How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D?

How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D?

How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Itamar Raz, MD

Itamar Raz, MD

Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel